Simulations Plus Advances Agentic Drug Development with NVIDIA BioNeMo Agent Toolkit
New capabilities connect AI agents, scientific literature, and validated computational engines to accelerate model-informed drug development
Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and AI-accelerated drug development that helps advance biopharma innovation, today announced it is building the agentic layer of Composer, its AI-native platform for model-informed drug development, using the NVIDIA BioNeMo Agent Toolkit.
The initiative expands the companies’ collaboration announced in May 2026, extending their work in GPU-accelerated simulation and AI-assisted modeling workflows into agentic drug development. Together, the companies are combining AI reasoning, scientific literature, validated computational engines, and scalable compute within a scientific workflow.
The announcement coincides with NVIDIA’s introduction of the BioNeMo Agent Toolkit at the BIO International Convention.
The integration is initially focused on two areas:
Grounding scientific reasoning in trusted evidence
Composer agents are expected to leverage NVIDIA Nemotron™ Parse to extract and structure information from scientific literature, enabling agents to retrieve relevant evidence while maintaining provenance back to the original source. Researchers can trace recommendations and conclusions to the supporting literature and data.
Accelerating quantitative systems pharmacology at scale
The companies are together advancing nvQSP, a collaborative development initiative focused on CUDA-optimized ordinary differential equation (ODE) solvers for quantitative systems pharmacology (QSP). By accelerating computationally intensive simulations on NVIDIA accelerated computing infrastructure, nvQSP enables scientists to explore larger parameter spaces, evaluate more hypotheses, and iterate more rapidly across complex biological systems. nvQSP builds on the companies’ previously announced work to accelerate computationally intensive QSP workflows using GPU-optimized simulation technology.
These capabilities are being incorporated into Composer, allowing agents to coordinate scientific workflows while remaining rooted in validated computational engines and source-based evidence.
"AI can help scientists explore more possibilities, but in drug development those insights must remain reproducible, explainable, and grounded in validated science," said Erik Guffrey, Co-Chief Product and Technology Officer of Simulations Plus. "By combining the NVIDIA BioNeMo Agent Toolkit with our scientific engines, we’re building agents that seek to accelerate scientific work while preserving the rigor required for critical development decisions."
The initiative reflects Simulations Plus’ strategy to connect AI reasoning, scientific knowledge, and validated computational engines within a unified environment for model-informed drug development.
"We believe agentic AI represents an important evolution in how scientists interact with models, data, and scientific knowledge," said Shawn O’Connor, Chief Executive Officer of Simulations Plus. "Our goal is to help researchers move from question to insight more efficiently while keeping validated science at the center of decision-making."
About Simulations Plus, Inc.
Simulations Plus is a global leader in model-informed and AI-accelerated drug development. We create value for our clients by accelerating the discovery, development, and commercialization of pharmaceuticals and other products through innovative science-based software and consulting solutions. For more information, visit www.simulations-plus.com.
Forward-Looking Statements
Except for historical information, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties. Words like "believe," "will", "can", "believe", "expect," "anticipate" and similar expressions (or the negative of such terms, as well as other words or expressions referencing future events, conditions or circumstances) mean that these are our best estimates as of this writing, but there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Forward-looking statements in this press release include, but are not limited to, statements regarding: the development and incorporation of agentic AI capabilities into the Company's Composer platform; the anticipated benefits, functionality, performance, and availability of Composer agents and related technologies; the use of the NVIDIA BioNeMo Agent Toolkit and NVIDIA technologies within the Company's products and workflows; the advancement and expected capabilities of nvQSP and GPU-accelerated quantitative systems pharmacology workflows; the ability of AI-enabled technologies to accelerate scientific workflows, improve research productivity, enhance model-informed drug development, or generate actionable insights; the anticipated benefits of the collaboration between Simulations Plus and NVIDIA; and the Company's strategic plans, objectives, and expectations regarding AI, computational modeling, and drug development technologies. Factors that could cause or contribute to such differences include, but are not limited to: our ability to successfully develop, integrate, and commercialize new technologies, including AI-enabled products and capabilities; customer acceptance and adoption of new software products, enhancements, and services; our ability to maintain and strengthen our competitive position; our reliance on third-party technology providers, platforms, and infrastructure; the availability, performance, and cost of computing resources; our ability to attract, retain, and develop qualified personnel; changes in the pharmaceutical, biotechnology, and healthcare industries; regulatory, legal, and compliance developments relating to artificial intelligence and other technologies; general economic, business, and market conditions; and our ability to finance growth initiatives. Further information on our risk factors is contained in our quarterly, annual and current reports and filed with the U.S. Securities and Exchange Commission.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260623040671/en/
Financial Profiles
Lisa Fortuna
310-622-8251
slp@finprofiles.com